TY - JOUR
T1 - Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p- substitutedphenyl)methanes
T2 - A new class of peroxisome proliferator-activated receptor γ agonists
AU - Kassouf, Wassim
AU - Chintharlapalli, Sudhakar
AU - Abdelrahim, Maen
AU - Nelkin, Gina
AU - Safe, Stephen
AU - Kamat, Ashish M.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/1/1
Y1 - 2006/1/1
N2 - 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) substituents have been identified as a new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that exhibit antitumorigenic activity. The PPARγ-active C-DIMs have not previously been studied against bladder cancer. We investigated the effects of the PPARγ-active C-DIMs on bladder cancer cells in vitro and bladder tumors in vivo. In this study, the PPARγ-active compounds inhibited the proliferation of KU7 and 253J-BV bladder cancer cells, and the corresponding IC50 values were 5 to 10 and 1 to 5 μmol/L, respectively. In the less responsive KU7 cells, the PPARγ agonists induced caveolin-1 and p21 expression but no changes in cyclin D1 or p27; in 253J-BV cells, the PPARγ agonists did not affect caveolin-1, cyclin D1, or p27 expression but induced p21 protein. In KU7 cells, induction of caveolin-1 by each of the PPARγ agonists was significantly down-regulated after cotreatment with the PPARγ antagonist GW9662. DIM-C-pPhCF3 (60 mg/kg thrice a week for 4 weeks) inhibited the growth of implanted KU7 orthotopic and s.c. tumors by 32% and 60%, respectively, and produced a corresponding decrease in proliferation index. Treatment of KU7 cells with DIM-C-pPhCF3 also elevated caveolin-1 expression by 25% to 30%, suggesting a role for this protein in mediating the antitumorigenic activity of DIM-C-pPhCF3 in bladder cancer.
AB - 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) substituents have been identified as a new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that exhibit antitumorigenic activity. The PPARγ-active C-DIMs have not previously been studied against bladder cancer. We investigated the effects of the PPARγ-active C-DIMs on bladder cancer cells in vitro and bladder tumors in vivo. In this study, the PPARγ-active compounds inhibited the proliferation of KU7 and 253J-BV bladder cancer cells, and the corresponding IC50 values were 5 to 10 and 1 to 5 μmol/L, respectively. In the less responsive KU7 cells, the PPARγ agonists induced caveolin-1 and p21 expression but no changes in cyclin D1 or p27; in 253J-BV cells, the PPARγ agonists did not affect caveolin-1, cyclin D1, or p27 expression but induced p21 protein. In KU7 cells, induction of caveolin-1 by each of the PPARγ agonists was significantly down-regulated after cotreatment with the PPARγ antagonist GW9662. DIM-C-pPhCF3 (60 mg/kg thrice a week for 4 weeks) inhibited the growth of implanted KU7 orthotopic and s.c. tumors by 32% and 60%, respectively, and produced a corresponding decrease in proliferation index. Treatment of KU7 cells with DIM-C-pPhCF3 also elevated caveolin-1 expression by 25% to 30%, suggesting a role for this protein in mediating the antitumorigenic activity of DIM-C-pPhCF3 in bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=31544464135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31544464135&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-2755
DO - 10.1158/0008-5472.CAN-05-2755
M3 - Article
C2 - 16397256
AN - SCOPUS:31544464135
SN - 0008-5472
VL - 66
SP - 412
EP - 418
JO - Cancer research
JF - Cancer research
IS - 1
ER -